Cyclacel Pharmaceuticals logo
Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer
13 juil. 2020 07h00 HE | Cyclacel
-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – ...
Quanta.png
Quanta Publishes Study in PLOS ONE: Enhancement of Solute Clearance using Pulsatile Push-Pull Dialysate Flow for SC+
03 mars 2020 02h00 HE | Quanta Dialysis Technologies
Quanta Publishes Study in PLOS ONE:Enhancement of Solute Clearance using Pulsatile Push-Pull Dialysate Flow for SC+ Alcester, Warwickshire, UK, 03 March 2020: Quanta Dialysis Technologies Ltd...
Phase 2 Clinical Dat
Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection
02 août 2018 14h00 HE | Summit Therapeutics plc
Microbiome Damage Caused by Current Treatments May Lead to Disease RecurrenceRidinilazole Reduced Recurrence Rates by 59% versus Standard of Care Vancomycin OXFORD, U.K. and CAMBRIDGE, Mass., Aug. ...
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
12 mai 2015 05h08 HE | Mesoblast
NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...